- Latest available (Revised)
- Point in Time (01/08/2003)
- Original (As made)
Version Superseded: 15/10/2003
Point in time view as at 01/08/2003.
There are currently no known outstanding effects for the The Misuse of Drugs Regulations 2001.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 3
1. The following substances and products, namely -U.K.
(a)Bufotenine
Cannabinol
Cannabinol derivatives not being dronabinol or its stereoisomers
Cannabis and cannabis resin
Cathinone
Coca leaf
Concentrate of poppy-straw
Eticyclidine
Etryptamine
Lysergamide
Lysergide and otherN-alkyl derivatives of lysergamide
Mescaline
Methcathinone
Psilocin
Raw opium
Rolicyclidine
Tenocyclidine
4-Bromo-2,5-dimethoxy-a-methylphenethylamine
N,N-Diethyltryptamine
N,N-Dimethyltryptamine
2,5-Dimethoxy-a,4-dimethylphenethylamine
N-Hydroxy-tenamphetamine
4-Methyl-aminorex
(b)any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
(c)the following phenethylamine derivatives, namely—
Allyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
2-Amino-1-(3,4-dimethoxyphenyl)ethanol
Benzyl(a-methyl-3,4-methylenedioxyphenethyl)amine
4-Bromo-b,2,5-trimethoxyphenethylamine
N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
Cyclopropylmethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine
2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
2-(1,4-Dimethoxy-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethylamine
a,a-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(a-methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
b-Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(a-Methyl-3,4-methylenedioxyphenethylamino)ethanol
a-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O-Methyl-N-(a-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
a-Methyl-4-(methylthio)phenethylamine
b,3,4,5-Tetramethoxyphenethylamine
b,2,5-Trimethoxy-4-methylphenethylamine
(d)any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, anN-alkylphenethylamine,a-methylphenethylamine, anN-alkyl-a-methylphenethylamine,a-ethylphenethylamine, or anN-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;
(e)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -
(i)by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
(ii)by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
(iii)by substitution in the piperidine ring with alkyl or alkenyl groups;
(iv)by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
(v)by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
(vi)by replacement of theN-propionyl group by another acyl group;
(f)any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say—
(i)by replacement of the l-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
(ii)by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
(iii)by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
(iv)by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
(v)by formation of an N-oxide or of a quaternary base.
2. Any stereoisomeric form of a substance specified in paragraph 1.U.K.
3. Any ester or ether of a substance specified in paragraph 1 or 2.U.K.
4. Any salt of a substance specified in any of paragraphs 1 to 3.U.K.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1. The following substances and products, namely—U.K.
Acetorphine
Alfentanil
Allylprodine
Alphacetylmethadol
Alphameprodine
Alphamethadol
Alphaprodine
Anileridine
Benzethidine
Benzylmorphine (3-benzylmorphine)
Betacetylmethadol
Betameprodine
Betamethadol
Betaprodine
Bezitramide
Carfentanil
Clonitazene
Cocaine
Desomorphine
Dextromoramide
Diamorphine
Diampromide
Diethylthiambutene
Difenoxin
Dihydrocodeinone O-carboxymethyloxime
[F1Dihydroetorphine]
Dihydromorphine
Dimenoxadole
Dimepheptanol
Dimethylthiambutene
Dioxaphetyl butyrate
Diphenoxylate
Dipipanone
Dronabinol
Drotebanol
Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine
Ethylmethylthiambutene
Etonitazene
Etorphine
Etoxeridine
Fentanyl
Furethidine
Hydrocodone
Hydromorphinol
Hydromorphone
Hydroxypethidine
Isomethadone
Ketobemidone
Levomethorphan
Levomoramide
Levophenacylmorphan
Levorphanol
Lofentanil
Medicinal opium
Metazocine
Methadone
Methadyl acetate
Methyldesorphine
Methyldihydromorphine (6-methyldihydromorphine)
Metopon
Morpheridine
Morphine
Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives
Myrophine
Nicomorphine
Noracymethadol
Norlevorphanol
Normethadone
Normorphine
Norpipanone
Oxycodone
Oxymorphone
Pethidine
Phenadoxone
Phenampromide
Phenazocine
Phencyclidine
Phenomorphan
Phenoperidine
Piminodine
Piritramide
Proheptazine
Properidine
Racemethorphan
Racemoramide
Racemorphan
[F2Remifentanil]
Sufentanil
Thebacon
Thebaine
Tilidate
Trimeperidine
Zipeprol
4-Cyano-2-dimethylamino-4,4-diphenylbutane
4-Cyano-1-methyl-4-phenylpiperidine
2-Methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid
a-Methylphenethylhydroxylamine
1-Methyl-4-phenylpiperidine-4-carboxylic acid
4-Phenylpiperidine-4-carboxylic acid ethyl ester
Textual Amendments
F1Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(a)
F2Word in Sch. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(2)(b)
2. Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan.U.K.
3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.U.K.
4. Any salt of a substance specified in any of paragraphs 1 to 3.U.K.
5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.U.K.
6. The following substances and products, namely—U.K.
Acetyldihydrocodeine | Methaqualone |
Amphetamine | Methylamphetamine |
Codeine | Methylphenidate |
Dextropropoxyphene | Nicocodine |
Dihydrocodeine | Nicodicodine (6-nicotinoyldihydrocodeine) |
Ethylmorphine (3-ethylmorphine) | Norcodeine |
Fenethylline | Phenmetrazine |
Glutethimide | Pholcodine |
Lefetamine | Propiram |
Mecloqualone | Quinalbarbitone |
7. Any stereoisomeric form of a substance specified in paragraph 6.U.K.
8. Any salt of a substance specified in paragraph 6 or 7.U.K.
9. Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1. The following substances, namely—U.K.
(a)
Benzphetamine | Mephentermine |
Buprenorphine | Meprobamate |
Cathine | Methylphenobarbitone |
Chlorphentermine | Methyprylone |
Diethylpropion | Pentazocine |
Ethchlorvynol | Phendimetrazine |
Ethinamate | Phentermine |
Flunitrazepam | Pipradrol |
Mazindol | Temazepam |
(b)any 5, 5 disubstituted barbituric acid not being quinalbarbitone.
2. Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine.U.K.
3. Any salt of a substance specified in paragraph 1 or 2.U.K.
4. Any preparation or other product containing a substance specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1. The following substances and products, namely—U.K.
Alprazolam
Aminorex
Bromazepam
Brotizolam
Camazepam
Chlordiazepoxide
Clobazam
Clonazepam
Clorazepic acid
Clotiazepam
Cloxazolam
Delorazepam
Diazepam
Estazolam
Ethyl loflazepate
Fencamfamin
Fenproporex
Fludiazepam
Flurazepam
Halazepam
Haloxazolam
[F34-Hydroxy-n-butyric acid]
Ketazolam
Loprazolam
Lorazepam
Lormetazepam
Medazepam
Mefenorex
Mesocarb
Midazolam
Nimetazepam
Nitrazepam
Nordazepam
Oxazepam
Oxazolam
Pemoline
Pinazepam
Prazepam
Pyrovalerone
Tetrazepam
Triazolam
N-Ethylamphetamine
[F4Zolpidem]
Textual Amendments
F3Words in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(a)
F4Word in Sch. 4 Pt. 1 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(3)(b)
2. Any stereoisomeric form of a substance specified in paragraph 1.U.K.
3. Any salt of a substance specified in paragraph 1 or 2.U.K.
4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.U.K.
1. The following substances, namely—U.K.
[F54-Androstene-3, 17-dione]
[F55-Androstene-3, 17 diol]
Atamestane
Bolandiol
Bolasterone
Bolazine
Boldenone
Bolenol
Bolmantalate
Calusterone
4-Chloromethandienone
Clostebol
Drostanolone
Enestebol
Epitiostanol
Ethyloestrenol
Fluoxymesterone
Formebolone
Furazabol
Mebolazine
Mepitiostane
Mesabolone
Mestanolone
Mesterolone
Methandienone
Methandriol
Methenolone
Methyltestosterone
Metribolone
Mibolerone
Nandrolone
[F619-Nor-4-Androstene-3, 17-dione]
[F619-Nor-5-Androstene-3, 17 diol]
Norboletone
Norclostebol
Norethandrolone
Ovandrotone
Oxabolone
Oxandrolone
Oxymesterone
Oxymetholone
Prasterone
Propetandrol
Quinbolone
Roxibolone
Silandrone
Stanolone
Stanozolol
Stenbolone
Testosterone
Thiomesterone
Trenbolone
Textual Amendments
F5Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(a)
F6Words in Sch. 4 Pt. 2 para. 1 inserted (1.7.2003) by The Misuse of Drugs (Amendment) Regulations 2003 (S.I. 2003/1432), regs. 1, 2(4)(b)
2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -U.K.
(a)by further substitution at position 17 by a methyl or ethyl group;
(b)by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;
(c)by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
(d)by fusion of ring A with a heterocyclic system.
3. Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.U.K.
4. The following substances, namely—U.K.
Chorionic Gonadotrophin (HCG)
Clenbuterol
Non-human chorionic gonadotrophin
Somatotropin
Somatrem
Somatropin
5. Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.U.K.
6. Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.U.K.
7. Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.U.K.
Regulation 3
1.—(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.U.K.
(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts.
2. Any preparation of cocaine containing not more than 0.1% of cocaine calculated as cocaine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the cocaine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.U.K.
3. Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.U.K.
4. Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.U.K.
5. Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin.U.K.
6. Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.U.K.
7. Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose.U.K.
8. Any powder of ipecacuanha and opium comprising—U.K.
10% opium, in powder,
10% ipecacuanha root, in powder, well mixed with
80% of any other powdered ingredient containing no controlled drug.
9. Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.U.K.
Regulation 19
Date on which supply received | Name | Address | Amount obtained | Form in which obtained |
---|---|---|---|---|
of person or firm from whom obtained | ||||
Date on which transaction effected | Name | Address | Particulars as to licence or authority of person or firm supplied to be in possession | Amount supplied | Form in which supplied |
---|---|---|---|---|---|
of person or firm supplied | |||||
Regulation 28
Regulations revoked | References |
---|---|
The Misuse of Drugs Regulations 1985 | S.I. 1985/2066 |
The Misuse of Drugs (Amendment) Regulations 1986 | S.I. 1986/2330 |
The Misuse of Drugs (Amendment) Regulations 1988 | S.I. 1988/916 |
The Misuse of Drugs (Amendment) Regulations 1989 | S.I. 1989/1460 |
The Misuse of Drugs (Amendment) Regulations 1990 | S.I. 1990/2630 |
The Misuse of Drugs (Amendment) Regulations 1995 | S.I. 1995/2048 |
The Misuse of Drugs (Amendment No. 2) Regulations 1995 | S.I. 1995/3244 |
The Misuse of Drugs (Amendment) Regulations 1996 | S.I. 1996/1597 |
The Misuse of Drugs (Amendment) Regulations 1998 | S.I. 1998/882 |
The Misuse of Drugs (Amendment) Regulations 1999 | S.I. 1999/1404 |
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: